LOSCOCCO, GIUSEPPE GAETANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.860
AS - Asia 2.894
EU - Europa 2.648
SA - Sud America 429
Continente sconosciuto - Info sul continente non disponibili 121
AF - Africa 86
OC - Oceania 38
Totale 10.076
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.698
RU - Federazione Russa 918
CN - Cina 851
IT - Italia 839
SG - Singapore 788
BR - Brasile 326
HK - Hong Kong 326
KR - Corea 272
VN - Vietnam 220
BD - Bangladesh 133
FI - Finlandia 123
IE - Irlanda 122
CA - Canada 109
GB - Regno Unito 106
FR - Francia 102
DE - Germania 99
SE - Svezia 88
NL - Olanda 78
IN - India 69
CH - Svizzera 63
ID - Indonesia 47
AU - Australia 38
JP - Giappone 38
AR - Argentina 37
ES - Italia 34
JO - Giordania 34
MX - Messico 28
EC - Ecuador 22
TR - Turchia 20
TW - Taiwan 17
CZ - Repubblica Ceca 16
NG - Nigeria 14
ZA - Sudafrica 14
CO - Colombia 13
AT - Austria 12
MY - Malesia 12
CI - Costa d'Avorio 10
IQ - Iraq 10
PL - Polonia 10
CL - Cile 9
GR - Grecia 9
UA - Ucraina 9
MA - Marocco 8
PK - Pakistan 8
VE - Venezuela 8
BJ - Benin 7
JM - Giamaica 7
UZ - Uzbekistan 7
EG - Egitto 6
KE - Kenya 6
PY - Paraguay 6
SA - Arabia Saudita 6
DZ - Algeria 5
KZ - Kazakistan 5
PH - Filippine 5
PE - Perù 4
SI - Slovenia 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AL - Albania 3
DO - Repubblica Dominicana 3
IL - Israele 3
NP - Nepal 3
OM - Oman 3
SC - Seychelles 3
AE - Emirati Arabi Uniti 2
BB - Barbados 2
CR - Costa Rica 2
DK - Danimarca 2
GE - Georgia 2
HU - Ungheria 2
KW - Kuwait 2
LT - Lituania 2
LU - Lussemburgo 2
LV - Lettonia 2
PS - Palestinian Territory 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TN - Tunisia 2
AW - Aruba 1
AZ - Azerbaigian 1
BS - Bahamas 1
BT - Bhutan 1
BW - Botswana 1
CG - Congo 1
CM - Camerun 1
CU - Cuba 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
ET - Etiopia 1
GH - Ghana 1
HN - Honduras 1
HR - Croazia 1
LB - Libano 1
MM - Myanmar 1
MU - Mauritius 1
PR - Porto Rico 1
RO - Romania 1
RS - Serbia 1
Totale 9.951
Salva come PNG Salva come JPEG
Città #
Santa Clara 987
Singapore 576
Ashburn 491
Hefei 307
Hong Kong 284
Seoul 269
San Jose 234
Milan 139
Dublin 122
Council Bluffs 120
Los Angeles 109
Fairfield 101
Chandler 97
Beijing 95
Ho Chi Minh City 80
New York 76
Helsinki 74
Florence 69
Moscow 64
Buffalo 62
Lauterbourg 62
Houston 61
Bern 59
Rome 52
Hanoi 44
Kent 43
Munich 43
Altamura 42
Lawrence 42
Woodbridge 42
Dallas 41
Seattle 40
Boston 34
London 33
Melbourne 33
Cambridge 31
Phoenix 31
The Dalles 31
Jakarta 30
São Paulo 28
Wilmington 27
Shanghai 26
Turku 26
Princeton 25
Toronto 25
Mumbai 23
Paris 23
Tokyo 23
Figino 21
Lappeenranta 21
Bologna 18
Boardman 17
Brooklyn 16
Montreal 16
Frankfurt am Main 15
Naples 15
Prague 15
Amsterdam 14
Barcelona 14
Bengaluru 14
Taipei 14
Chicago 13
Abuja 12
Ealing 12
Manchester 12
Ann Arbor 11
Atlanta 11
Modena 11
Orem 11
San Diego 11
Turin 11
Vancouver 11
Waltham 11
Abidjan 10
Chennai 10
Fiesole 10
Guayaquil 10
Mexico City 10
Rio de Janeiro 10
The Hague 10
City of London 9
Düsseldorf 9
Johannesburg 9
Miano 9
San Francisco 9
Vienna 9
Ankara 8
Bremen 8
Catania 8
Da Nang 8
Denver 8
Falkenstein 8
Genoa 8
Haiphong 8
Hamilton 8
Philadelphia 8
Tianjin 8
Warsaw 8
Amman 7
Biên Hòa 7
Totale 5.957
Salva come PNG Salva come JPEG
Nome #
Essential Thrombocythemia 462
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 278
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 203
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 199
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 198
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 198
Kaposi Sarcoma in a patient treated with Ruxolitinib 197
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 196
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 193
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 192
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 190
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 190
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 188
CALR mutation burden in essential thrombocythemia and disease outcome 186
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 186
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 182
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 181
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 181
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 168
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 167
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 164
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 163
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 163
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 162
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies 160
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm 158
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 157
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 157
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 156
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 154
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 152
Mutations and thrombosis in essential thrombocythemia 150
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data 144
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 144
Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases 142
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 141
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 141
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 140
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis 139
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 136
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 133
Myeloid sarcoma: more and less than a distinct entity 130
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives 129
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19 127
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia 125
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial 125
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease 123
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis 120
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker 120
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 120
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses 116
Visceral Leishmaniasis 113
Changes in neutrophil-to-lymphocyte ratio in patients with polycythemia vera treated with ruxolitinib reflect JAK2 variant allele frequency 110
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 110
Bone marrow involvement in small cell lung cancer 106
When and how to transplant in myelofibrosis – recent trends 105
Clinical and Prognostic Correlates of the Reticulin-Collagen-Osteosclerosis (RCO) Score in Primary Myelofibrosis 105
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 100
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates 100
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives 100
Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management 81
Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms 80
PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features 80
Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy 73
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms 67
TP53 Mutations in Myeloproliferative Neoplasms: Context‐Dependent Evaluation of Prognostic Relevance 46
Essential Thrombocythemia 32
Aspirin Regimens in EsSential thrombocythemia (ARES) Investigators. Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 23
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm 22
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera 18
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images 17
Understanding Triple Negative Myeloproliferative Neoplasms and Identifying Molecular Drivers 15
Triple A Plus (AAA +) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients 15
TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance 15
Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities 14
null 2
null 1
Totale 10.076
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.084
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.084
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022142 0 0 1 2 3 3 0 40 15 3 30 45
2022/2023626 51 117 40 29 28 88 68 30 56 12 15 92
2023/2024501 28 35 58 24 56 68 22 93 9 47 36 25
2024/20253.020 85 236 156 403 805 458 115 142 119 101 172 228
2025/20264.652 479 627 624 509 382 129 402 210 273 302 293 422
2026/2027824 246 185 393 0 0 0 0 0 0 0 0 0
Totale 10.076